Get the Stockscreener App
9.04
3.32%
-0.31
After Hours:
9.05
0.01
+0.11%
Niagen Bioscience Inc stock is traded at $9.04, with a volume of 1.08M.
It is down -3.32% in the last 24 hours and down -29.43% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$9.35
Open:
$9.2
24h Volume:
1.08M
Relative Volume:
1.01
Market Cap:
$712.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.00%
1M Performance:
-29.43%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.77
$9.20
1-Week Range:
$8.77
$9.96
52-Week Range:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
9.04 | 750.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
When is Niagen Bioscience Inc. stock expected to show significant growthAdvanced Screener Report With Low Risk - jammulinksnews.com
Niagen Bioscience (NASDAQ:NAGE) Stock Price Up 6%Here's What Happened - MarketBeat
Is Niagen Bioscience Inc. a growth stock or a value stockFinancial News Tracker With High Returns - jammulinksnews.com
How strong is Niagen Bioscience Inc. company’s balance sheetReal Time Watchlist To Watch Now - jammulinksnews.com
Real time scanner hits for Niagen Bioscience Inc. explainedRisk Managed Intraday Trade Alerts Increase in Volume - metal.it
What technical models suggest about Niagen Bioscience Inc.’s comebackChart Driven High Reward Trading Setup Presented - metal.it
Niagen Bioscience And Two Other High Growth Stocks With Strong Insider Ownership - Yahoo Finance
Niagen Bioscience Subsidiary Signs Supply Agreement - TipRanks
Bollinger Band Squeeze Points to Volatility in Niagen Bioscience Inc.Short Term Buy Zone Stock Alerts Signal Entry - beatles.ru
Can Niagen Bioscience Inc. hit a new high this monthHigh Yield Stock Screening Results Explained - metal.it
What makes Niagen Bioscience Inc. stock price move sharplyWeekly Growth Stock Entry Point Alerts Highlighted - metal.it
Why is Niagen Bioscience Inc. stock attracting strong analyst attentionAdvanced Screener Report With Low Risk - jammulinksnews.com
Niagen Bioscience Inc. May Be Forming Higher Low — Chartwatchers AlertMarket Momentum Signal Generator Shows Trends - metal.it
What is the dividend policy of Niagen Bioscience Inc. stockExceptional gains - jammulinksnews.com
What is Niagen Bioscience Inc. company’s growth strategyAchieve rapid wealth accumulation through smart investing - jammulinksnews.com
Should I hold or sell Niagen Bioscience Inc. stock in 2025Invest confidently with professional guidance - jammulinksnews.com
How does Niagen Bioscience Inc. generate profit in a changing economyMaximize your investment portfolio’s performance - jammulinksnews.com
Niagen Bioscience Inc. Stock Analysis and ForecastHigh-yield capital appreciation - PrintWeekIndia
What drives Niagen Bioscience Inc. stock priceFree Market Volatility Navigation Tips - PrintWeekIndia
Does Niagen Bioscience Inc. stock pay reliable dividendsTriple-digit return opportunities - jammulinksnews.com
Is Niagen Bioscience Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance
Niagen Bioscience to Report Second Quarter 2025 Financial Result - GuruFocus
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - Business Wire
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap dropped US$129m last week; individual investors who hold 33% were hit as were institutions - simplywall.st
What analysts say about Niagen Bioscience Inc. stockFree Consultation - Autocar Professional
Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy - MSN
Niagen Bioscience (NASDAQ:NAGE) Shares Down 4%Time to Sell? - MarketBeat
Niagen Bioscience Inc Stock (NAGE) Financials Data
There is no financial data for Niagen Bioscience Inc (NAGE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Niagen Bioscience Inc Stock (NAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):